化合物UCM-1036 T67729

Product Introduction
Bioactivity


英文名: UCM-1306

描述: UCM-1306 是具有口服活性的人多巴胺 D1 受体变构调节剂 (PAM)。UCM-1306 增加结合在人和小鼠 D1 受体的内源性多巴胺 (DA) 效应。UCM-1306可以改善运动症状，解决与长期帕金森病(PD) 相关的关键共病认知障碍。

体外活性: UCM-1306 (1-10 μM) 以浓度-反应方式提高CAMP，EC50=60 nM[1]。

体内活性: UCM-1306 (p.o.; C57BL/6J mice) has good brain penetration and oral availability. The plasma concentration can be quantified within 8 hours, and Tmax is 0.5 hours. UCM-1306 (1 mg/kg; ip) enhances cocaine induced hyperactivity in adult mice. UCM-1306 (1 mg/kg; ip) helps to consolidate the formation of long-term memory [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45.0 mg/mL (161.1 mM)


关键字: UCM 1306 | UCM1306 | UCM1036 | UCM-1306

相关产品: Chlorprothixene hydrochloride | Etilevodopa hydrochloride | Nortriptyline hydrochloride | SCH-23390 hydrochloride | Pimozide-d4 | Aplindore Fumarate | Bromocriptine mesylate | Rotigotine | Ziprasidone | Azaperone

相关库: Anti-Neurodegenerative Disease Compound Library | Neurotransmitter Receptor Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | GPCR Compound Library | Bioactive Compound Library

化合物UCM-1036 T67729信息由TargetMol中国为您提供，如您想了解更多关于化合物UCM-1036 T67729报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途